Nicozid (Isoniazid)

Isoniazid is activated inside the mycobacterial cell by the KatG enzyme. The activated form then inhibits the InhA enzyme, blocking the synthesis of mycolic acids that are essential for the bacterial cell wall, leading to bacterial death.

The dose of isoniazid is individualized by the prescribing clinician based on factors such as patient weight, age, disease severity, and renal or hepatic function. No fixed regimen is provided here; the prescriber determines the appropriate amount.

Safety data are limited. Isoniazid may be used during pregnancy or lactation only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should assess each case and consider pyridoxine supplementation to reduce neuropathy risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative in first‑line TB therapy is rifampicin, which has a different mechanism— inhibition of bacterial RNA synthesis. Isoniazid is more specific for mycolic‑acid synthesis, while rifampicin offers broader activity against other bacteria. Both are used together in standard regimens to enhance efficacy and prevent resistance.

Nicozid should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The product should be handled in a clean environment, and any unused portion should be discarded according to local regulations for injectable medicines.

Nicozid is supplied for intravenous administration. It is typically infused over a prescribed period under clinical supervision, using aseptic technique and appropriate infusion sets. The exact rate and duration are determined by the treating physician based on patient condition.

The most serious adverse events include hepatotoxicity (which can progress to hepatitis or liver failure), severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and rare hematologic disorders like aplastic anemia. Patients should be monitored regularly for liver function abnormalities and any signs of allergic reaction.

Nicozid is contraindicated in individuals with known hypersensitivity to isoniazid or any of its excipients, and in patients with severe pre‑existing liver disease. Caution is also advised for those with peripheral neuropathy, pregnant or lactating women unless the benefit justifies the risk, and patients taking interacting medications without appropriate monitoring.